| Primary |
| Product Used For Unknown Indication |
27.9% |
| Immunosuppression |
23.3% |
| Renal Transplant |
17.4% |
| Immunosuppressant Drug Therapy |
3.5% |
| Myasthenia Gravis |
3.5% |
| Systemic Lupus Erythematosus |
3.5% |
| Intentional Overdose |
2.3% |
| Liver Transplant |
2.3% |
| Pemphigus |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
2.3% |
| Biliary Cirrhosis Primary |
1.2% |
| Blood Cholesterol Increased |
1.2% |
| Cardiac Operation |
1.2% |
| Depression |
1.2% |
| Dermatitis |
1.2% |
| Hypertension |
1.2% |
| Insomnia |
1.2% |
| Lung Transplant |
1.2% |
| Lupus Erythematosus |
1.2% |
| Neuropathy Peripheral |
1.2% |
|
| Vomiting |
12.5% |
| Thrombocytopenia |
8.3% |
| Tonsil Cancer |
8.3% |
| Accidental Overdose |
4.2% |
| Arteriosclerosis |
4.2% |
| Basal Cell Carcinoma |
4.2% |
| Breast Cancer |
4.2% |
| Contusion |
4.2% |
| Disease Progression |
4.2% |
| Dyspepsia |
4.2% |
| Exposure Via Father |
4.2% |
| Inflammatory Bowel Disease |
4.2% |
| Injury |
4.2% |
| Insomnia |
4.2% |
| Laryngeal Cancer |
4.2% |
| Lung Neoplasm Malignant |
4.2% |
| Nasopharyngitis |
4.2% |
| Oesophageal Squamous Cell Carcinoma |
4.2% |
| Palpitations |
4.2% |
| Polyarthritis |
4.2% |
|
| Secondary |
| Product Used For Unknown Indication |
49.2% |
| Renal Transplant |
11.3% |
| Immunosuppression |
6.8% |
| Prophylaxis |
5.1% |
| Hepatitis C |
3.9% |
| Prophylaxis Against Transplant Rejection |
3.9% |
| Prophylaxis Against Graft Versus Host Disease |
3.5% |
| Rhodococcus Infection |
2.9% |
| Immunosuppressant Drug Therapy |
2.6% |
| Dermatitis Herpetiformis |
1.6% |
| Systemic Lupus Erythematosus |
1.6% |
| Liver Transplant |
1.3% |
| Antifungal Prophylaxis |
1.0% |
| Bone Marrow Conditioning Regimen |
1.0% |
| Lung Transplant |
1.0% |
| Stem Cell Transplant |
1.0% |
| B-cell Lymphoma |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Gout |
0.6% |
| Histiocytosis Haematophagic |
0.6% |
|
| Liver Transplant Rejection |
25.9% |
| Interstitial Lung Disease |
14.8% |
| Off Label Use |
11.1% |
| Renal Tubular Necrosis |
7.4% |
| Portal Vein Thrombosis |
5.6% |
| Urine Output Decreased |
5.6% |
| Pigmentation Disorder |
3.7% |
| Thrombocytopenia |
3.7% |
| Acute Graft Versus Host Disease In Skin |
1.9% |
| Alveolar Proteinosis |
1.9% |
| Aspergillus Infection |
1.9% |
| Breast Cancer |
1.9% |
| Death |
1.9% |
| Exposure During Pregnancy |
1.9% |
| Headache |
1.9% |
| Hepatitis E |
1.9% |
| Insomnia |
1.9% |
| Leiomyosarcoma |
1.9% |
| Lupus Nephritis |
1.9% |
| Maternal Drugs Affecting Foetus |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
43.2% |
| Immunosuppression |
9.3% |
| Prophylaxis |
5.7% |
| Bone Marrow Conditioning Regimen |
3.7% |
| Renal Transplant |
3.7% |
| Immunosuppressant Drug Therapy |
3.4% |
| Prophylaxis Against Transplant Rejection |
3.1% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Pyrexia |
2.7% |
| Hypertension |
2.6% |
| Nausea |
2.6% |
| Systemic Lupus Erythematosus |
2.3% |
| Liver Transplant |
2.1% |
| Neoplasm Malignant |
2.0% |
| Pain |
2.0% |
| Abdominal Pain Upper |
1.9% |
| Heart Transplant |
1.7% |
| Neutropenia |
1.7% |
| Rheumatoid Arthritis |
1.7% |
| Sarcoidosis |
1.7% |
|
| Pyrexia |
10.5% |
| Vomiting |
10.5% |
| Immunosuppressant Drug Level Increased |
7.9% |
| Death |
6.6% |
| Transplant Rejection |
6.6% |
| Off Label Use |
5.3% |
| Cardio-respiratory Arrest |
3.9% |
| Crohn's Disease |
3.9% |
| Leukoencephalopathy |
3.9% |
| Neoplasm Malignant |
3.9% |
| Renal Impairment |
3.9% |
| Renal Tubular Necrosis |
3.9% |
| Rhodococcus Infection |
3.9% |
| Tachycardia |
3.9% |
| Thrombotic Microangiopathy |
3.9% |
| Urinary Tract Infection |
3.9% |
| Visual Impairment |
3.9% |
| White Blood Cell Count Increased |
3.9% |
| Cerebral Haemorrhage |
2.6% |
| Graft Versus Host Disease |
2.6% |
|
